| Literature DB >> 32497212 |
Nguyen Van Vinh Chau1, Vo Thanh Lam1, Nguyen Thanh Dung1, Lam Minh Yen2, Ngo Ngoc Quang Minh3, Le Manh Hung1, Nghiem My Ngoc1, Nguyen Tri Dung4, Dinh Nguyen Huy Man1, Lam Anh Nguyet2, Le Thanh Hoang Nhat2, Le Nguyen Truc Nhu2, Nguyen Thi Han Ny2, Nguyen Thi Thu Hong2, Evelyne Kestelyn2,5, Nguyen Thi Phuong Dung2, Tran Chanh Xuan6, Tran Tinh Hien2,5, Nguyen Thanh Phong1, Tran Nguyen Hoang Tu1, Ronald B Geskus2,5, Tran Tan Thanh2, Nguyen Thanh Truong1, Nguyen Tan Binh7, Tang Chi Thuong7, Guy Thwaites2,5, Le Van Tan2.
Abstract
BACKGROUND: Little is known about the natural history of asymptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.Entities:
Keywords: COVID-19; SARS-CoV-2; Vietnam; coronaviruses; pandemic
Mesh:
Substances:
Year: 2020 PMID: 32497212 PMCID: PMC7314145 DOI: 10.1093/cid/ciaa711
Source DB: PubMed Journal: Clin Infect Dis ISSN: 1058-4838 Impact factor: 9.079
Figure 1.Timelines of containment strategies applied in Vietnam and in Ho Chi Minh City (HCMC) since the beginning of 2020 as the epidemic/pandemic progresses alongside the implementation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reverse-transcription polymerase chain reaction (RT-PCR) testing and the duration of the clinical study. *Initially China, followed by Korea, other European counties (Italy, France, United Kingdom, etc.) and the United States.
Figure 2.Settings and the clinical study. A, Map showing the location of the Hospital for Tropical Diseases (HTD) main campus and its designated coronavirus disease 2019 centers in Cu Chi, where the clinical study was conducted, and Can Gio. B, Flowchart illustrating the results of reverse-transcription polymerase chain reaction screening of quarantined people between 10 March and 5 April 2020, and the enrollment of patients in the clinical study. *Extrapolated from data extracted from the HTD database system. During this period, HTD tested a total of 11 052 cases, accounting for 80% of isolated people in Ho Chi Minh City (HCMC). **The remaining cases were either treated at the main campus of HTD in HCMC or at the other designated isolation center (Can Gio Hospital). #One was transferred to the main campus of HTD 10 hours after admission and 2 were transferred from the main campus of HTD after 5 and 6 days of hospitalization and were not enrolled because of enrollment competition. Maps were obtained from https://mapchart.net/. Abbreviations: HCMC, Ho Chi Minh City; HTD, Hospital for Tropical Diseases; PCR, polymerase chain reaction; RT-PCR, reverse-transcription polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
Demographics of Imported Cases and Cases of Locally Acquired Infection
| Characteristic | Locally Acquired Infections (n = 14) | Imported Casesa (n = 16) |
|---|---|---|
| Female sex, No. (%) | 4 (29) | 11 (69) |
| Age, y, median (range) | 30.5 (23–51) | 21.5 (16–60) |
| Asymptomatic, No. (%) | 7 (50) | 6 (38) |
aDefined as cases arriving in Vietnam from abroad and positive for severe acute respiratory syndrome coronavirus 2 as part of airport quarantine and reverse-transcription polymerase chain reaction screening.
Baseline Characteristics of the Study Participants
| Characteristic | All (N = 30) | Symptomatic (n = 17) | Asymptomatic (n = 13) |
|---|---|---|---|
| Age, y, median (range) | 29 (16–60) | 27 (18–58) | 30 (16–60) |
| Sex (female/male), No./No. | 15/15 | 9/8 | 6/7 |
| Arriving in Vietnam from abroad, No. (%) | 16 (53) | 10 (59) | 6 (47) |
| Locally acquired infection, No. (%) | 14 (47) | 7 (41) | 7 (53) |
| Nationality, No. (%) | |||
| Vietnamese | 19 (63) | 12 (71) | 7 (53) |
| Others | 11 (37)a | 5 (29)b | 6 (46)c |
| Days from confirmed diagnosis to enrollment, median (range) | 2 (2–5) | 2 (0–3) | 2 (1–5) |
| Days from admission to enrollment, median (range) | 1 (0–2) | 1 (0–2) | 1 (0–2) |
| Duration of stay, d | 16 (9–26) | 16 (11–26) | 15 (9–23) |
| Laboratory resultsd, median (range)/normal range | |||
| WBC count , ×103 per μL | 5.16 (3.1–9.9)/(4–11) | 5.0 (3.4–8.3) | 5.51 (3.15–4.83) |
| Lymphocyte counts, ×103 per μL | 1.65 (0.56–2.94)/(1.5–4) | 1.47 (0.56–2.94) | 1.88 (1.17–2.5) |
| Hemoglobin, g/dL | 14.3 (10–17.3)/(13–18) | 14.4 (11.6–16.8) | 14.15 (10–17.3) |
| Hematocrit, % | 35.5 (28.5–42.3)/(37–52) | 36.5 (28.5–42.3) | 36 (35.78–42.27) |
| Platelet count/μL | 257 (130–414)/(150–450) | 249 (130–414) | 265.5 (174–321) |
| Glucose, mmol/L | 85 (6–340)e/(70–130) | 84.2 (68–340)f | 101.65 (64–146)g |
| Creatinine, mg/dL | 1.0 (0.9–1.5)h/(0.5–1.2) | 1.0 (0.9–12.4)i | 1 (0.96–1.54)g |
| AST, U/L | 22.5 (15.4–56.8)e/(< 40) | 22.5 (17.4–56.8)i | 17.4 (15.4–32.4)g |
| ALT, U/L | 22.3 (9.7–44.9)/(< 37) | 24 (10.2–34.8)i | 19.15 (9.7–44.9)g |
| Clinical signs/symptomsj, No. (%) | |||
| Fever | 8 (27) | 8 (47) | NA |
| Cough | 10 (33) | 10 (59) | NA |
| Rhinorrhea | 3 (10) | 3 (18) | NA |
| Fatigue | 1 (3) | 1 (6) | NA |
| Diarrhea | 3 (10) | 3 (18) | NA |
| Sore throat | 6 (20) | 6 (36) | NA |
| Muscle pain | 3 (10) | 3 (18) | NA |
| Headache | 2 (7) | 2 (12) | NA |
| Abdominal pain | 1 (3) | 1 (6) | NA |
| Lost sense of smell | 3 (10) | 3 (18) | NA |
| Comorbidity | 2 (7) | 2 (12)k | 0 |
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; NA, not applicable; WBC, white blood cell.
aBrazil (n = 3), United Kingdom (UK) (n = 3), Canada (n = 2), United States (n = 1), Czech Republic (n = 1), Italy (n = 1).
bUK (n = 2), Canada (n = 1), United States (n = 1), Czech Republic (n = 1).
cBrazil (n = 3), UK (n = 1), Canada (n = 1), Italy (n = 1).
dOne participant had blood collection on day 2; 2 participants on day 3; and 1 participant on day 4 after admission.
en = 17.
n = 10.
gn = 6.
hn = 18.
in = 11.
jOthers (nausea, vomiting, short breathing, bleeding, and taste disorder) were also recorded, but none presented with these signs/symptoms.
kDegenerative spine in 1 and diabetes in 1.
Figure 3.Comparison of cycle threshold values of severe acute respiratory syndrome coronavirus 2 real-time reverse-transcription polymerase chain reaction (RT-PCR) assays obtained from nasopharyngeal/throat swabs (NTSs) and saliva. A, Data include results of RT-PCR analysis of all available NTS and saliva samples collected from 30 participants at enrollment. B, Data only include results of RT-PCR analysis of paired NTS and saliva samples of 6 asymptomatic and 12 symptomatic patients who had both sample types collected at enrollment. Abbreviations: Ct, cycle threshold; NTS, nasopharyngeal/throat swab.
Figure 4.Trends in cycle threshold (Ct) values and viral detection probability in nasopharyngeal/throat swabs over the course of hospitalization. A, Changes of Ct values relatively reflect the level of viral load. B, Dynamics of viral detection probability from enrollment onward. Each dot represents 1 observed value (A) or the mean value (ie, frequency) per day (B); lines indicate mean and shades indicate 95% confidence interval. Abbreviations: Ct, cycle threshold; PCR, polymerase chain reaction.
Figure 5.Illustration of cases with an epidemiological link with community transmission cluster 2. Red circles indicate symptomatic patients, whereas blue circles indicate asymptomatic individuals. Patients shown on the large open circle are those who first came to a local bar on 14 March 2020. Arrows indicate patients who tested positive for severe acute respiratory syndrome coronavirus 2 after having contact with individuals who attended the event on 14 March 2020. *Reflecting the period from the first contacts among individuals shown on the large open circle (14 March 2020) to the time when local health authorities completed the contact tracing activities and reverse-transcription polymerase chain reaction screening of the contacts (6 April 2020). Patient numbers correspond to the numbers presented in Supplementary Figure 2. Abbreviation: P, patient.